

INSTALLATION et UTILISATION de ClinTrial Refer IFM



L'application **ClinTrial Refer**, disponible sur smartphone, met à disposition des soignants les informations sur les études en cours de recrutement et les sites d'investigation en France et en Belgique pour les études IFM, et nous espérons bientôt des études industrielles dans le myélome

Si vous avez déjà installé l'application pour accéder aux études du Lysa (que nous remercions pour leurs précieux conseils) il suffit de modifier dans l'onglet My apps, le site préféré et sélectionner IFM pour l'ajouter.


Sinon suivez les étapes suivantes

Recherchez l'application **ClinTrial Refer** dans l'Apple store ou le Play store selon votre système d'exploitation


Ou téléchargez à partir du site : <https://clintrial.org.au/>




L'Application ClinTrial Refer est commune a de nombreuses organisations principalement en Australie, un sous dossier IFM permet de filtrer les études.



A la première connexion passez par signup, ensuite ce sera login




Identifiez-vous avec votre email



Qui sera vérifié par l'envoi d'un lien mail



Sur la boîte mail, la confirmation est reçue et l'application informe de la vérification



Verify Account

An email with a link for verification has been sent to email ID:

mo-petillon@chru-lille.fr

Confirm your account by checking your email now. Click the link sent to your nominated email to verify your account

Email Verified

[Resend Link](#)

Puis renseignez les champs de la page profil

18:14

... 4G 50

Tell us about yourself

Enter below details to complete your profile.

First Name

Last Name

Select User Profession



dd/mm/yyyy



Email Address

mo-petillon@chru-lille.fr

FR +33 Mobile Number

Location

Password

.....




Confirm Password

.....



☐ I would like to hear more about Healthy Volunteer Trials.

Continue



Sélectionnez le sous site de l'IFM en application par défaut (et ajoutez le Lysa pour les études Lymphome si utile)

18:17 ... 4G 50

← Skip for later

Select Default Apps

Select default apps to your account.



Haematology WA, Australia



Healthy Volunteers



Intergroupe Francophone du Myélome



LYSA



Maridulu Budyari Gumat - SPHERE



Melanoma and Skin Cancer Trials



Melanoma Institute Australia

Continue

18:17 ... 4G 50



Select Primary App

Select primary app to your account.



Intergroupe Francophone du Myélome



Continue

18:17 ... 4G 50



Terms and Conditions & Privacy Policy

Terms and Conditions:

Copyright

This product incorporates software and/or data which is owned by South Eastern Sydney Local Health District (SESLHD) and Sydney Local Health District (SLHD) (in association with the Haematology Clinical research Network, NSW Health) © 2013

Condition of Download - Release and Indemnity

Prior to downloading this ClinTrial Refer App (the App), the user agrees, in consideration for, and as a condition to, being able to download the App, that the user releases SESLHD and SLHD (the Licensors) in respect of all liability for loss, damage or injury which may be suffered by the user or any other person arising from or in connection with the App; and further the user agrees to indemnify the Licensors in respect of all liability for loss, damage or injury, which may be suffered by or against any person arising from or in connection with that user's use of the App.

I Agree to the T&C's

Default App Settings

Edit your default app settings below

Intergroupe Francophone du Myélome

Push Notifications

Notify me of new trials

Set as Primary App

Pour la navigation, cliquer sur une étude pour avoir les détails ou rechercher par mots clefs, ou localisation

18:17

18:19

18:20

Intergroupe Francophone du My...



Search Trials

Available Trials (6)

CARRISMM IFM 2017-04
Evaluation of the Impact of the Update Multiple Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Prognostic Evaluation of Smoldering Myeloma (CARRISMM)

CONFIRM IFM 2018-07
A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

IFM 2014-01
Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of

Search Trials in Intergroupe Francophone du Myélome

Search for a trial using one or more filters

Apply Search

Reset

Select health condition

Select primary sponsor

Enter location

Select status

Enter keywords

Advanced Filters

Search for a trial using advanced filters

Haematology, Open, relapsed

Save Search

Refine Search

Search Results (2)

CONFIRM IFM 2018-07
A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

IFM 2014-01
Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic

Les informations sont actualisées chaque mois

18:21

18:21

IFM 2014-01

NCT03683277

Phase 2

Open

Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic

Eligibility

Trial Summary

Available Locations

Other Details

Primary Sponsor

 Intergroupe Francophone du Myelome

Available Locations

 CH Avignon Henri Duffaut
Recruiting

 CH Bayonne de la Côte Basque
Recruiting

 CH Dunkerque
Recruiting

 CH Périgueux
Recruiting

 CHD Vendée la Roche sur Yon
Recruiting

 CHRU de Tours / Centre Henri Kaplan
Recruiting

 CHRU Nantes - Hôtel Dieu
Recruiting